Literature DB >> 8936685

Novel uses of thyroid hormones in patients with affective disorders.

A J Prange1.   

Abstract

Hormones of the thyroid axis have been used to treat patients with any of several mental illnesses. However, in recent decades interest has focused almost exclusively on depression, though thyroid hormones, mainly thyroxine (T4), are used with lithium in rapid cycling bipolar disorder, a condition in which depression and mania rapidly alternate. In depression L-triiodothyronine (T3) has been used in preference to T4 because of its rapid onset and offset of action. In women starting treatment, T3 hastens the onset of therapeutic action of standard antidepressant drugs. It fails to do so in depressed men, who anyway respond faster than women to standard antidepressants. Standard drugs fail to produce satisfactory improvement in one-quarter to one-third of depressed patients. Then, in both men and women, T3 converts about two-thirds of drug failures to successes in rapid fashion. Lithium, which has antithyroid properties, produces a similar conversion rate. The majority of depressed patients are grossly euthyroid, but many show one or another subtle change in thyroid axis activity. However, the thyroid state of patients has not been matched systematically with their response to thyroid hormone augmentation. It seems likely that a tendency toward hypothyroidism can predispose to depression, but when depression occurs in a euthyroid patient, the thyroid axis is often invoked in the process of restitution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8936685     DOI: 10.1089/thy.1996.6.537

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  7 in total

1.  Effects of experimental increases and decreases in thyroxine levels on the extent of cataleptic freezing reactions in rats.

Authors:  A V Kulikov; M A Tikhonova; E I Lebedeva; V F Chugui; N K Popova
Journal:  Neurosci Behav Physiol       Date:  2005-09

2.  [Prevalence of thyroid disorders in patients diagnosed with depression].

Authors:  M J Muñoz-Cruzado Poce; A J García Navas; M L Moreno Gómez; R Garratón Juliá; A Marcelo Martínez; A J Madueño Caro
Journal:  Aten Primaria       Date:  2000 Jul-Aug       Impact factor: 1.137

3.  Decreased anxiety- and depression-like behaviors and hyperactivity in a type 3 deiodinase-deficient mouse showing brain thyrotoxicosis and peripheral hypothyroidism.

Authors:  J Patrizia Stohn; M Elena Martinez; Arturo Hernandez
Journal:  Psychoneuroendocrinology       Date:  2016-08-24       Impact factor: 4.905

Review 4.  Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.

Authors:  Paul J Carlson; Jaskaran B Singh; Carlos A Zarate; Wayne C Drevets; Husseini K Manji
Journal:  NeuroRx       Date:  2006-01

Review 5.  Update on augmentation of antidepressant response in resistant depression.

Authors:  Charles DeBattista; Anna Lembke
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

Review 6.  The Historical Development of Immunoendocrine Concepts of Psychiatric Disorders and Their Therapy.

Authors:  Holger Steinberg; Kenneth C Kirkby; Hubertus Himmerich
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

Review 7.  Hypothyroidism and Depression: A Narrative Review.

Authors:  Surya P Nuguru; Sriker Rachakonda; Shravani Sripathi; Mashal I Khan; Naomi Patel; Roja T Meda
Journal:  Cureus       Date:  2022-08-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.